Verteporfin photodynamic therapy for central serous chorioretinopathy

Verteporfin photodynamic therapy for central serous chorioretinopathy - PDT for CSC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020677

Enrollment

Registered

2016-02-01

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central serous chorioretinopathy

Interventions

6mg/m2 verteporfin (Visudyne) is infused over 10 minutes. 15 minutes after beginning the infusion, the total light energy delivered to the area of hyparpermiability was 50J/cm2 for 43 seconds by Semi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: presence of serous retinal detachment presence of leakage on fluorescein angiography and abnomality dilated choroidal veseles and hyperpermiability on indocyanine angiography

Exclusion criteria

Exclusion criteria: patients with other retinal diseases photosensitivity

Design outcomes

Primary

Measure	Time frame
Visual acuity	—

Secondary

Measure	Time frame
central retinal thickness central choroidal thickness	—

Countries

Japan

Contacts

Public ContactNagai Yoshimi

Kansai Medical University Ophthalmology

nagaiy@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026